2025-09-14 - Analysis Report
Okay, here's an analysis of Merck & Co. (MRK) based on the provided data, presented in English with numerical summaries and analysis.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** MRK (Merck & Co Inc)
*   **Description:** Merck & Co., Inc. is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing a wide range of healthcare solutions.

*   **MRK Cumulative Return:** -9.08%
*   **VOO (S&P 500) Cumulative Return:** 89.18%
*   **Absolute Divergence:** -162.3
    *   **Max Divergence:** 23.2
    *   **Min Divergence:** -166.4
    *   **Relative Divergence:** 2.2

**Analysis:** MRK has significantly underperformed the S&P 500 over the period analyzed. The cumulative return difference is substantial. The "Relative Divergence" suggests that MRK's underperformance is near the worst it has been relative to the S&P 500 within the historical data (2.2% of the divergence range).

**Alpha, Beta Analysis Table**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | 2.0%   | 0.0%   | 0.0%    | 0.9    | 134.1  |
| 2016-2018  | 33.0%  | 66.4%  | 38.0%   | 0.2    | 182.1  |
| 2017-2019  | 53.0%  | 66.4%  | 30.0%   | 0.2    | 216.8  |
| 2018-2020  | 19.0%  | 66.4%  | -8.0%   | 0.1    | 195.0  |
| 2019-2021  | -2.0%  | 65.6%  | -51.0%  | 0.0    | 191.4  |
| 2020-2022  | 13.0%  | 69.4%  | 6.0%    | 0.0    | 277.1  |
| 2021-2023  | 31.0%  | 69.4%  | 11.0%   | 0.2    | 272.3  |
| 2022-2024  | -7.0%  | 69.4%  | -34.0%  | 0.2    | 248.5  |
| 2023-2025  | -62.0% | 71.5%  | -116.0% | 0.4    | 206.8  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** The CAGR varies significantly across the periods, with strong growth in 2017-2019 but a substantial decline in 2023-2025.
*   **MDD (Maximum Drawdown):** The MDD is consistently high, indicating significant potential for losses during the periods.
*   **Alpha:** Alpha, which measures performance relative to a benchmark, is generally positive in earlier periods but becomes increasingly negative, particularly in the most recent period (-116.0%), suggesting significant underperformance.
*   **Beta:** Beta is generally low, suggesting that MRK is less volatile than the overall market.
*   **Cap(B) (Market Capitalization in Billions):** The market capitalization has fluctuated over time.

**2. Recent Stock Price Movements**

*   **Current Price:** 82.81
*   **Previous Close:** 85.15
*   **Change:** -2.75
*   **5-Day Moving Average:** 84.14
*   **20-Day Moving Average:** 84.57
*   **60-Day Moving Average:** 82.35

**Analysis:** The stock price has recently decreased, as indicated by the negative change. The 5-day and 20-day moving averages are above the current price, suggesting a short-term downward trend.  The price has crossed over the 60-day moving average which is potentially signalling a downtrend. The relatively large negative change from the previous close indicates a notable downward price movement.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI (Relative Strength Index):** 31.05
*   **PPO (Percentage Price Oscillator):** -0.254
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **20-Day Relative Divergence Change:** -2.5 (Negative - Short-term decline)
*   **Expected Return:** -1329.4%

**Analysis:**

*   **MRI:** The Market Risk Indicator suggests low risk.
*   **RSI:** The RSI is below 30, which is generally considered oversold territory, potentially indicating a buying opportunity.
*   **PPO:** The negative PPO indicates a bearish trend.
*   **Hybrid Signal:** The hybrid signal recommends buying 80% of cash but with caution, likely due to the MRI.
*   **Relative Divergence Change:** The negative change in relative divergence confirms the recent short-term decline.
*   **Expected Return:** The extremely negative expected return is highly concerning and suggests significant challenges for MRK relative to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **[2025-09-14]** 2 Healthcare Dividend Stocks to Buy and Hold (Motley Fool)
*   **[2025-09-14]** Leerink Partners Remains Bullish on Merck & Co. (MRK) (Insider Monkey)
*   **[2025-09-13]** Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
*   **[2025-09-12]** Exclusive-AstraZeneca pauses $270 million investment in Britain (Reuters)
*   **[2025-09-12]** Merck & Co., Inc. (MRK) Reports Positive Topline Results from its Phase 3 CORALreef Lipids Trial (Insider Monkey)
*   **[2025-09-12]** Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects (Zacks)

**Analysis:** Recent news is mixed.  Leerink Partners remains bullish, and there are positive results from a Phase 3 trial. However, news about AstraZeneca pausing investment in Britain could create sector-wide uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (~1.96 on a 1-5 scale)
*   **Opinions:** 24
*   **Target Price:**
    *   Average: 102.33
    *   High: 141.00
    *   Low: 82.00
*   **Recent Rating Changes:** Not specified (all listed as " â†’ ")

**Analysis:** Analyst consensus is a "Buy" with a significant upside potential based on the average target price. However, the low target price is close to the current price. The lack of recent rating changes is not providing any immediate directional signals.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2025-08-05 | 2.15 | 16.11 B$   |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated over the recent quarters.  There is no consistent upward or downward trend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-06-30 | $48.99B   | 9.04% |
| 2025-03-31 | $48.34B   | 10.51%|
| 2024-12-31 | $46.31B   | 8.08% |
| 2024-09-30 | $44.50B   | 7.09% |
| 2024-06-30 | $43.58B   | 12.52%|

**Analysis:**

*   **Revenue and Profit Margin:** Revenue has been relatively stable, although there are fluctuations from quarter to quarter. Profit margins are consistently high.
*   **Equity and ROE (Return on Equity):** Equity has been increasing, indicating growth in the company's net assets. ROE, a measure of profitability, fluctuates, indicating varying levels of efficiency in generating profits from shareholders' equity.

**7. Overall Summary and Conclusion**

Merck & Co. (MRK) presents a mixed picture:

*   **Underperformance:**  Significant underperformance compared to the S&P 500.
*   **Technical Indicators:** Oversold RSI potentially indicating a short-term buying opportunity.  A downtrend based on price crossing below the 60-day moving average.
*   **Analyst Sentiment:** Positive analyst consensus, but target prices have a wide range.
*   **Financials:** Relatively stable revenue, high profit margins, and increasing equity.
*   **News:** Mixed news flow, with positive trial results but also sector-related concerns.
*   **Expected Return:** The extremely negative expected return is a major concern.

**Conclusion:**  While MRK has some positive attributes (high profit margins, oversold RSI), the significant underperformance relative to the S&P 500, negative long-term expected return, and recent price decline suggest caution.  Further investigation into the reasons for underperformance and the validity of the negative expected return is warranted before making any investment decisions. Recent earning data also supports holding off an investment at this time.
